Cargando…
Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity
Nintedanib is a tyrosine kinase inhibitor of fibroblast growth factor-, vascular endothelial growth factor-, and platelet-derived growth factor receptors. These three receptors promote new blood vessel formation and maintenance, which is essential for tumor growth and spread. Several trials have sho...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449572/ https://www.ncbi.nlm.nih.gov/pubmed/37637045 http://dx.doi.org/10.3389/fonc.2023.1086214 |
_version_ | 1785094982668910592 |
---|---|
author | Yan, Shu Xue, Shuyu Wang, Tiantian Gao, Ruihang Zeng, Hanqiao Wang, Qianmeng Jia, Xiaojing |
author_facet | Yan, Shu Xue, Shuyu Wang, Tiantian Gao, Ruihang Zeng, Hanqiao Wang, Qianmeng Jia, Xiaojing |
author_sort | Yan, Shu |
collection | PubMed |
description | Nintedanib is a tyrosine kinase inhibitor of fibroblast growth factor-, vascular endothelial growth factor-, and platelet-derived growth factor receptors. These three receptors promote new blood vessel formation and maintenance, which is essential for tumor growth and spread. Several trials have shown that nintedanib plays a substantial role in treating patients with non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis. Recently, several clinical trials of nintedanib to treat NSCLC have been reported. In this review, we focus on our current understanding of nintedanib treatment for advanced NSCLC patients and summarize the literature on using nintedanib in radiation-induced lung toxicity and the efficacy and tolerability of nintedanib. |
format | Online Article Text |
id | pubmed-10449572 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104495722023-08-25 Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity Yan, Shu Xue, Shuyu Wang, Tiantian Gao, Ruihang Zeng, Hanqiao Wang, Qianmeng Jia, Xiaojing Front Oncol Oncology Nintedanib is a tyrosine kinase inhibitor of fibroblast growth factor-, vascular endothelial growth factor-, and platelet-derived growth factor receptors. These three receptors promote new blood vessel formation and maintenance, which is essential for tumor growth and spread. Several trials have shown that nintedanib plays a substantial role in treating patients with non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis. Recently, several clinical trials of nintedanib to treat NSCLC have been reported. In this review, we focus on our current understanding of nintedanib treatment for advanced NSCLC patients and summarize the literature on using nintedanib in radiation-induced lung toxicity and the efficacy and tolerability of nintedanib. Frontiers Media S.A. 2023-08-10 /pmc/articles/PMC10449572/ /pubmed/37637045 http://dx.doi.org/10.3389/fonc.2023.1086214 Text en Copyright © 2023 Yan, Xue, Wang, Gao, Zeng, Wang and Jia https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yan, Shu Xue, Shuyu Wang, Tiantian Gao, Ruihang Zeng, Hanqiao Wang, Qianmeng Jia, Xiaojing Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity |
title | Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity |
title_full | Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity |
title_fullStr | Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity |
title_full_unstemmed | Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity |
title_short | Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity |
title_sort | efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449572/ https://www.ncbi.nlm.nih.gov/pubmed/37637045 http://dx.doi.org/10.3389/fonc.2023.1086214 |
work_keys_str_mv | AT yanshu efficacyandsafetyofnintedanibinpatientswithnonsmallcelllungcancerandnovelinsightsinradiationinducedlungtoxicity AT xueshuyu efficacyandsafetyofnintedanibinpatientswithnonsmallcelllungcancerandnovelinsightsinradiationinducedlungtoxicity AT wangtiantian efficacyandsafetyofnintedanibinpatientswithnonsmallcelllungcancerandnovelinsightsinradiationinducedlungtoxicity AT gaoruihang efficacyandsafetyofnintedanibinpatientswithnonsmallcelllungcancerandnovelinsightsinradiationinducedlungtoxicity AT zenghanqiao efficacyandsafetyofnintedanibinpatientswithnonsmallcelllungcancerandnovelinsightsinradiationinducedlungtoxicity AT wangqianmeng efficacyandsafetyofnintedanibinpatientswithnonsmallcelllungcancerandnovelinsightsinradiationinducedlungtoxicity AT jiaxiaojing efficacyandsafetyofnintedanibinpatientswithnonsmallcelllungcancerandnovelinsightsinradiationinducedlungtoxicity |